Suzhou Baimai Biopharmaceutical
Innovative drug research and development platform for "new generation tumor immunotherapy technology".
Market cap
-
Enterprise valuation
CAD15—23m (Dealroom.co estimates Dec 2022.)
China (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series A | |
* | CNY20.0m | Series A | |
| Total Funding | CAD7.5m | ||